ProQR to Participate in 8th Annual Evercore Healthcare Conference
Rhea-AI Summary
ProQR (Nasdaq: PRQR) will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025 at 8:20 AM ET. The presentation is part of the company’s investor outreach about its Axiomer RNA editing platform. Webcast access and live details are available from the company’s Investors & Media website section at www.proqr.com under "Events". Archived webcasts will be available for approximately 30 days after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, PRQR declined 9.40%, reflecting a notable negative market reaction. Argus tracked a peak move of +5.6% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $21M from the company's valuation, bringing the market cap to $205M at that time. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PRQR fell -3.88% on high volume, while close peers were mixed: ACIU recently showed -4.04% downside momentum, EDIT and THRD were down, but SLN and especially VOR were up, suggesting stock-specific dynamics rather than a broad RNA/editing sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 01 | Investor conference | Neutral | -9.4% | Announcement of Evercore Healthcare Conference fireside chat and webcast access. |
| Nov 06 | Earnings update | Neutral | -7.1% | Q3 2025 results with CTA authorization, cash runway into mid-2027, wider loss. |
| Oct 20 | Clinical milestone | Positive | +9.7% | CCMO CTA authorization for AX-0810 enabling Phase 1 dosing in the Netherlands. |
| Oct 13 | Multiple conferences | Neutral | -5.0% | Participation in several October 2025 investor conferences and RNA editing panel. |
| Aug 07 | Earnings update | Neutral | -0.5% | Q2 2025 results, AX-0810 CTA submission, cash balance and net loss disclosure. |
Recent news and earnings, including neutral conference updates, often saw negative price reactions, while clinically meaningful pipeline milestones like AX-0810 CTA authorization drew the only clearly positive move.
Over the last few months ProQR highlighted progress in its RNA editing pipeline, including submitting a Clinical Trial Application for AX-0810 and later receiving CTA authorization for a Phase 1 study in the Netherlands. Q2 and Q3 2025 results emphasized cash runway into mid-2027 but also widening losses. Investor engagement stepped up via multiple conferences and a dedicated AX-0810 investor event. The Evercore fireside chat continues this outreach trend, following prior investor conferences and virtual events.
Market Pulse Summary
The stock moved -9.4% in the session following this news. A negative reaction despite a routine conference participation announcement fits a pattern where non-clinical or non-earnings news often preceded downside. Recent Q2 and Q3 2025 updates emphasized cash runway but also significant losses, which may have kept sentiment fragile. If selling accelerated, it could reflect investors fading non-data events and refocusing on fundamentals and the timing of future clinical readouts rather than conference exposure.
Key Terms
adar-mediated medical
rna editing medical
webcast technical
AI-generated analysis. Not financial advice.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025 at 8:20am ET.
Webcast details will be accessible from the “Investors & Media” section of ProQR’s website (www.proqr.com) under "Events". Archived webcasts will be available for approximately 30 days following the presentation date.
About Axiomer™
ProQR is pioneering a next-generation RNA base editing technology called Axiomer™, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer™ “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer™ EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
Learn more about ProQR at www.proqr.com.
Forward Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “continue,” "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our participation in this conference, statements regarding our business, technology, strategy, preclinical and clinical model data, our initial pipeline targets and the upcoming strategic priorities and milestones related thereto, the continued advancement of our lead development pipeline programs, including ongoing and planned clinical trials, expectations regarding regulatory feedback and the potential registrational pathway for AX-0810 in NTCP for cholestatic diseases, the anticipated timing of initial Phase 1 clinical data for our lead program, AX-0810, and clinical updates across multiple programs in 2025, our Axiomer™ platform, including the continued development and advancement of our Axiomer platform, the therapeutic potential of our Axiomer RNA editing oligonucleotides and product candidates, the timing, progress and results of our preclinical studies and other development activities, including the release of data related thereto, our patent estate, including our anticipated strength and our continued investment in it, as well as the timing of our clinical development, the potential of our technologies and product candidates, the collaboration with Lilly and the intended benefits thereof, including timing for data updates, potential milestones, exercise of an option to expand targets and the receipt of an opt-in payment, our ability to selectively form new partnerships and enter into future collaborations, and our financial position and cash-runway. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those expressed or implied by these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our most recent annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners whose operations and activities may be slowed or halted shortage and pressure on supply and logistics on the global market, economic sanctions and international tariffs; the likelihood of our preclinical and clinical programs being initiated and executed on timelines provided and reliance on our contract research organizations and predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners, including the collaboration with Lilly; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties; and risks related to macroeconomic conditions and market volatility resulting from global economic developments, geopolitical events and conflicts, high inflation, rising interest rates, tariffs and potential for significant changes in U.S. policies and regulatory environment. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
ProQR Therapeutics N.V.
Investor and media contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Investor contact:
Peter Kelleher
LifeSci Advisors
T: +1 617 430 7579
pkelleher@lifesciadvisors.com
FAQ
When will ProQR (PRQR) present at the Evercore Healthcare Conference?
How can investors watch the ProQR (PRQR) fireside chat webcast?
Will the ProQR (PRQR) Evercore webcast be available after the live event?
What topic will ProQR (PRQR) discuss at the Evercore Healthcare Conference?
Is there a scheduled time for the ProQR (PRQR) fireside chat at Evercore?
Where can I find the archived ProQR (PRQR) webcast after December 4, 2025?
